011517
0-35887 92 18 3169

J
92-2273 11/Lt



SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 or 15 (d)

For the quarterly period ended May 30, 1992
Commission file number 0-12991

THE LANGER BIOMECHANICS GROUP, INC.

(Exact name of registrant as specified in its charter.)

NEW YORK	11-2239561
(State or other jurisdiction of incorporation or organization.)	(I.R.S. Employer Identification No.)

21 EAST INDUSTRY COURT, DEER PARK, NY 11729

(Address of principal executive offices.) (Zip Code)

Registrant's telephone number, including area code (516) 667-1200

NOT APPLICABLE

Former name, former address and former fiscal year, if changed since last report.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES	X	NO	

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practical date.

Common Stock, $.02 Par Value -- 2,540,953 shares as of June 19, 1992

L3G
PROCESSED BY
11-11-V
JUL 10 1992

Microfilmed by
Q-Data Corp. - St. Petersburg, FL

INDEX

THE LANGER BIOMECHANICS GROUP, INC. AND SUBSIDIARIES

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Condensed Consolidated Balance Sheets -- May 30, 1992 and February 29, 1992.

Condensed Consolidated Statements of Operations -- Three months ended May 30, 1992 and May 31, 1991.

Condensed Consolidated Statements of Cash Flows -- Three months ended May 30, 1992 and May 31, 1991.

Notes to Condensed Consolidated Financial Statements -- Three months ended May 30, 1992.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

PART II. OTHER INFORMATION

None.

Signatures

PART I. FINANCIAL INFORMATION

THE LANGER BIOMECHANICS GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

Assets	May 30, 1992 (unaudited)	Feb. 29 1992
Current Assets:		
Cash and cash equivalents	$ 853,041	$ 919,447
Accounts receivable, net of allowance for doubtful accounts of $88,000 and $79,000, respectively	1,997,865	1,764,059
Inventories, net (Note 2)	1,440,309	1,445,809
Other current assets	406,770	372,265
Total current assets	4,697,985	4,501,580
Property and equipment, net	1,116,332	1,124,947
Equipment held for disposition	75,000	75,000
Other assets	248,945	248,630
	6,138,262	5,950,157
Liabilities and Stockholders' Equity		
Current Liabilities:		
Current maturities of notes payable	64,413	58,874
Accounts payable	176,152	153,044
Accrued liabilities:		
Accrued payroll and related payroll taxes	311,346	316,366
Unearned revenue	464,800	479,013
Other current liabilities	679,051	665,198
Total current liabilities	1,695,762	1,672,495
Long-term notes payable, net of current maturities	46,186	58,167
Long-term bank debt	1,000	1,000
Accrued pension expense	225,128	219,128
Unearned revenue	137,396	143,355
Capital lease obligations	51,835	57,835
Deferred Taxes	4,389	4,389
Minority interest in subsidiary	13,152	5,122
	2,174,848	2,161,491
Commitments and contingencies		
Stockholders' equity		
Common stock, $.02 par value. Authorized 10,000,000 shares; outstanding 2,540,953 shares respectively	50,820	50,820
Additional paid-in capital	6,241,775	6,241,775
Accumulated deficit	(2,054,224)	(2,234,346)
Aggregate adjustment resulting from translation of financial statements into U.S. dollars	0	5,374
Minimum pension liability adjustment	(274,957)	(274,957)
Total stockholders' equity	3,963,414	3,788,666
	$6,138,262	$5,950,157

See notes to condensed consolidated financial statements.

THE LANGER BIOMECHANICS GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended: May 30, 1992	May 31, 1991
Net sales (Note 3)	$3,226,832	$3,382,082
Cost of sales	1,728,988	1,760,471
Gross profit	1,497,844	1,621,611
Selling expenses	490,024	509,008
General and administrative expenses	808,489	1,424,895
Research and development expenses	21,942	76,208
Income (loss) from operations	177,389	(388,500)
Other Income, principally interest	28,816	52,697
	206,205	(335,803)
Other Expense, principally interest	6,009	37,763
Income (loss) before minority interest and income taxes	200,196	(373,566)
Minority Interest	8,030	16,634
Income (loss) before income taxes	192,166	(390,200)
Provision for income taxes	17,417	(19,510)
Net income (loss)	$ 174,749	$ (370,690)
Per share data (Note 1):		
Weighted average number of shares of common stock outstanding	2,679,580	2,586,238
Net income (loss) per share of common stock outstanding	$ 0.07	$ (0.14)

See notes to condensed consolidated financial statements.

THE LANGER BIOMECHANICS GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Three Months Ended: May 30, 1992	May 31, 1991
Cash flows from operating activities:		
Net income (loss)	$174,749	$(370,690)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:		
Deferred foreign tax benefit	-	(438)
Depreciation and amortization	75,973	366,857
Minority interest in income	8,030	16,634
Changes in operating assets and liabilities:		
Increase in accounts receivable	(233,806)	(44,267)
Decrease in inventories	5,500	53,756
(Increase) decrease in prepaid expenses and other assets	(34,820)	217,177
Increase in pension liability	6,000	-
Increase (decrease) in accounts payable and accrued liabilities	25,940	(337,234)
Decrease in unearned revenue	(20,172)	(7,689)
Net cash provided by (used in) operating activities	7,394	(105,894)
Cash flows from investing activities:		
Capital expenditures	(67,358)	(18,725)
Net cash used in investing activities	(67,358)	(18,725)
Cash flows from financing activities:		
Proceeds from exercise of stock options	-	6,750
Principal payments of notes payable	(6,442)	(27,542)
Net cash provided by (used in) financing activities	(6,442)	(20,792)
Net decrease in cash and cash equivalents	(66,406)	(145,411)
Cash and cash equivalents at beginning of year	919,447	1,667,599
Cash and cash equivalents at end of period	$853,041	$1,522,188
Supplemental disclosures of cash flow and non-cash flow information:		
Cash paid for interest	$ 6,061	$ 39,705
Capital lease obligations incurred for the purchase of new equipment	-	-

See notes to condensed consolidated financial statements.

THE LANGER BIOMECHANICS GROUP, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

May 30, 1992

NOTE 1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND OTHER MATTERS

A) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Operating results for the period ended May 30, 1992 are not necessarily indicative of the results that may be expected for the year ending February 28, 1993. For further information, refer to the consolidated statements and footnotes thereto for the fiscal year ended February 29, 1992 in the Company's 1992 Annual Report.

B) Income per Share

Net income (loss) per share includes the effect of common stock equivalents comprised of incentive stock options granted under the Company's qualified stock option plan and non-qualified stock options.

C) Provision for Income Taxes

The benefit from income taxes for period ended May 30, 1992 was calculated at an effective annual tax rate of 9% reflecting the utilization of available net operating loss carryforwards. Since SFAS No. 96 was implemented in fiscal 1989, the realization of a portion of the Company's net operating loss carryforwards was reflected as a reduction of the provision for income taxes, rather than an extraordinary item.

NOTE 2

The Company did not take a physical inventory as of May 30, 1992. Inventories and cost of sales for the interim period were based on the Company's perpetual inventory records.

	May 30, 1992 (unaudited)	February 29, 1992
Inventories consist of:		
Raw materials and supplies	1,281,395	1,290,565
Work-in-process	87,539	79,463
Finished goods	175,413	179,819
Total Inventories	1,544,347	1,549,847
Less: Allowance for obsolescence	104,038	104,038
Net Inventories	1,440,309	1,445,809

NOTE 3 - SEASONALITY

Revenues derived from the Company's sale of orthotic devices, a substantial portion of the Company's operations, have historically been significantly higher in the warmer months of the year.

investments and service charge income generated from the Company's accounts receivable. Other expense consists primarily of interest on the Company's bank debt and notes payable. Net other income was $23,000 for the first quarter compared with $15,000 in the comparable prior year's quarter representing an increase of 53.3%. This increase was achieved through reduction of bank debt.

MINORITY INTEREST

The Managing Director of our English subsidiary maintains a 33% ownership share of the business.

PROVISION FOR INCOME TAXES

The Company has provided an effective tax rate of 9% of pre-tax profits after utilizing available net operating loss carry forwards.

NET INCOME (LOSS)

The Company earned $175,000 or $.07 per share for the recently concluded quarter as compared to a loss of $371,000 or $(.14) per share generated in the prior year's quarter. This turnaround in profit was achieved through reduction of operating expenses.

LIQUIDITY AND CAPITAL RESOURCES

As of May 30, 1992, the Company had $253,000 in cash and cash equivalents. Working capital, as of May 30, 1992 was $3,002,000 versus $2,829,000 at February 29, 1992, an increase of $173,000. The Company also has a $1,750,000 revolving credit-term loan agreement. All but $1,000 remains unused. Under the terms of that agreement, the Company would have been able to borrow up to $1,741,000 as of May 30, 1992.

The Company believes its capital position is adequate to met anticipated cash needs for at least the next twelve months. The Company anticipates that capital expenditures over the next twelve months will be from $125,000 to $200,000.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

The Langer Biomechanics Group, Inc

(REGISTRANT)

DATE: July 1, 1992

By: _____
H. John Altorfer, President and Chief Executive Officer

By: _____
Donald M. Carbone, Vice President - Finance and Chief Financial Officers (Principal Financial Officer)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

The Langer Biomechanics Group, Inc.

(REGISTRANT)

DATE: July 1, 1992

By: /s/ H. JOHN ALTORFER
H. John Altorfer, President and Chief Executive Officer

By: /s/ DONALD M. CARBONE
Donald M. Carbone, Vice President - Finance and Chief Financial Officers (Principal Financial Officer)